Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model.
Fiche publication
Date publication
janvier 2018
Journal
Contrast media & molecular imaging
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRUNOTTE François, Pr FUMOLEAU Pierre, Pr DENAT Franck, Dr COLLIN Bertrand, Dr BELLAYE Pierre-Simon
Tous les auteurs :
Bellaye PS, Oudot A, Vrigneaud JM, Raguin O, Bichat F, Vaslin A, Maby-El Hajjami H, Zanna C, Vuagniaux G, Fumoleau P, Denat F, Brunotte F, Collin B
Lien Pubmed
Résumé
Debio 1143, a potent orally available SMAC mimetic, targets inhibitors of apoptosis proteins (IAPs) members and is currently in clinical trials. In this study, nuclear imaging evaluated the effects of Debio 1143 on tumor cell death and metabolism in a triple-negative breast cancer (TNBC) cell line (MDA-MB-231)-based animal model.
Référence
Contrast Media Mol Imaging. 2018 ;2018:8494031